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Progress in understanding neurodegenerative cell biology in Parkinson’s disease (PD) has been hampered by a lack of predictive
and relevant cellular models. In addition, the lack of an adequate in vitro human neuron cell-based model has been an obstacle
for the uncover of new drugs for treating PD. The ability to generate induced pluripotent stem cells (iPSCs) from PD patients and
a refined capacity to differentiate these iPSCs into DA neurons, the relevant disease cell type, promises a new paradigm in drug
development that positions human disease pathophysiology at the core of preclinical drug discovery. Disease models derived from
iPSC that manifest cellular disease phenotypes have been established for several monogenic diseases, but iPSC can likewise be used
for phenotype-based drug screens in complex diseases for which the underlying genetic mechanism is unknown. Here, we highlight
recent advances as well as limitations in the use of iPSC technology for modelling PD “in a dish” and for testing compounds against
human disease phenotypes in vitro. We discuss how iPSCs are being exploited to illuminate disease pathophysiology, identify novel
drug targets, and enhance the probability of clinical success of new drugs.
1. Introduction
Parkinson’s disease (PD) is the second most common neu-
rodegenerative disorder, characterized by a large number of
motor and nonmotor features that can affect function in a
variable degree.
The main pathological hallmark in PD is the loss of
midbrain dopaminergic (DA) neurons in the substantia
nigra pars compacta (SNpc) projecting to the striatum and
abnormal cytoplasmic inclusions enriched in α-synuclein,
the Lewy bodies, deposited in surviving neurons of the brain
[1–3].
There is no effective test for the diagnosis of PD; the dis-
order must be diagnosed based on clinical criteria. The main
clinical features are tremor at rest (unilateral, prominent in
the distal part of an extremity), rigidity (increased resistance
to move), akinesia or bradykinesia (slowness of movement),
postural instability, and other motor abnormalities. Other
symptoms include secondary motor symptoms such as
dystonia and dysphagia and nonmotor symptoms including
cognitive abnormalities, sleep disorders, and pain [3].
Despite the research efforts in this area, with new and
intriguing findings constantly being reported, at present,
PD is still an incurable disease, but treatment can improve
quality of life and functional capacity. To date, L-dopa in
combination with a peripheral dopa decarboxylase inhibitor
(benserazide or carbidopa) is the most effective therapy
as an initial treatment option. However, not all symptoms
respond equally to the drug; while tremor may be only
marginally reduced, bradykinesia and rigidity respond better.
Unfortunately, the treatment’s success is reduced over time,
and side effects increase, leaving the patient helpless [2].
Deep brain stimulation of the subthalamic nuclei is an
additional therapeutic option for PD patients but requires
surgical intervention.
Although all of these treatments provide symptomatic
relief, none of them is able to stop or reverse the progression
of the disease [1, 4]; for this reason there is a need for
novel therapeutic approaches. One alternative strategy is
cell-replacement therapy; in fact, clinical trials with intras-
triatal transplantation of human embryonic mesencephalic
tissue have shown that grafted DA neurons reinnervate the
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striatum, restore the striatal dopamine release, and, in some
patients, induce a major clinical benefit [5–7].
2. Molecular and Cellular Mechanism of
Parkinson’s Disease
The cause of PD is still unclear but most people suffering
this disorder have idiopathic PD (around 90%). A small
proportion of cases (approximately 10%), however, can be
attributed to known genetic factors that contribute to PD
complex pathogenesis.
Our understanding of the mechanisms underlying the
initiation and progression of PD began with the identi-
fication of mutations in the gene encoding α-synuclein
(SNCA) and the demonstration that α-synuclein is the
major component of Lewy bodies, present in the dis-
ease. Since then, at least 16 loci (designed as PARK1
to PARK16) and 11 genes have been associated with
inherited forms of parkinsonism, including, for exam-
ple, PARK1, PARK4/SNCA, PARK2/parkin, PARK5/ubiquitin
COOH-terminal hydrolase L1 (UCHL1), PARK6/PTEN-
induced kinase 1 (PINK1), PARK/DJ-1, and PARK8/Leucine-
rich repeat kinase 2 (LRRK2).
SNCA is an autosomal dominant gene that encodes the
protein α-synuclein, expressed abundantly in presynaptic
terminals of the neurons [8]. Several evidences support
the physiological functions of α-synuclein in the regu-
lation of vesicle dynamics at the presynaptic membrane
[9]. Mutations in SNCA increase in the self-assembly and
fibrillization of the protein that might lead to the formation
of the pathogenic inclusion bodies [9]. Another autosomal
dominant gene implicated in PD disease is the leucine-
rich repeat kinase 2 (LRRK2) [8, 10]. LRRK2 encodes a
large protein with multiple domains, including a Ras-like
GTP binding domain and a serine, threonine kinase domain
[10]. Mutations within these two functional domains have
been associated with PD [8, 10]. In normal conditions,
the function of LRRK2 kinase had been implicated in the
regulation of the cytoskeleton architecture [10]. In contrast,
Parkin is an autosomal recessive gene involved in PD [11].
This gene encodes the Parkin protein with an ubiquitin-like
sequence E3, which acts as a substrate for target proteins
bound to degrade by the ubiquitin proteasome system (UPS)
[11]. Inactivation of Parkin leads to reduction in UPS-
mediated degradation of target proteins [11] that could result
in protein accumulation. In addition, some data suggest
a possible function of Parkin in mitochondria, where the
protein is localized and promotes gene transcription [8,
11]. PINK1 is another autosomal recessive gene, whose
mutations might cause PD [11]. PINK1 encodes a protein
localized in the mitochondria membrane and its function
is associated with protection of cells from stress-induced
mitochondrial dysfunction [8, 11]. Interestingly, mutants of
Drosophila melanogaster lacking PINK1 display phenotypes
similar with those Parkin mutants; moreover the forced
expression of Parkin1 is able to rescue the mitochondrial
dysfunction caused by the absence of PINK1, suggesting their
interaction [9, 11]. Likewise, DJ-1 is a protein localized in
the mitochondria membrane and mutations in this gene
may cause autosomal recessive early-onset PD [8, 11]. Its
functions are related to the resistance of oxidative stress
[11].
The knowledge acquired of these proteins has revealed
pathways of neurodegeneration that may be shared between
inherited and sporadic PD. A set of data in different model
systems strongly suggest that mitochondrial dysfunction
plays a central role in clinically similar, early-onset autosomal
recessive PD forms caused by parkin and PINK1 and possibly
DJ-1 gene mutations [12, 13]. Further comprehension of
molecular and cellular mechanisms and interaction between
these proteins that causes PD with others is essential
to identify crucial and potential targets to improve the
treatment.
3. The Importance of In Vitro Models of PD
Most of the current knowledge about neurological diseases,
including PD, is gathered from postmortem studies due
to the limitations of live brain tissue. This restricts the
understanding of the disease progression and development,
since postmortem samples only represent the end-stage of
the disease. In addition, aspects of the exhibited pathology
in these samples could be secondary and not faithfully
reflect the exact disease phenotype on a cellular level.
Besides, interspecies differences make it difficult to accurately
simulate human neurological diseases in animal models.
Therefore, disease modelling by recapitulating the diseases
phenotype in vitro and in defined cell populations is an
important advancement and would make it possible to
understand cellular and molecular mechanisms of the neu-
rodegenerative disorder [14, 15]. Consider that investigation
of a multifactorial disease, such as PD, is more challenging
than monogenic disorders due to their complex genetic
backgrounds and because they are usually influenced by
environmental factors [15].
A progressive loss of substantia nigra DA neurons is the
main pathological hallmark of PD. Understanding the mech-
anism of neuronal cell death involved in PD may be of value
in developing neuroprotective therapies. However studying
neuronal cell death in human brains is extremely difficult
by several (methodological, practical) reasons. Development
of in vitro models of DA neurons can be powerful, as
they would allow the study of neurodegeneration as well as
novel therapeutic strategies [16]. Nevertheless, availability of
human DA neurons derived from fetal material is extremely
limited, and it has been difficult to examine directly toxicity
and/or protective effects of multiple factors in these neurons.
In this context, stem cells, particularly pluripotent stem
cells and neural stem/progenitor cells, are an excellent source
of cells, because of their availability, unlimited proliferation,
and plasticity to differentiate into other cell types. Moreover,
stem cells are an excellent alternative to ex vivo primary
cultures or established immortalized cell lines that can
contribute to our understanding of neuronal neurodegen-
erative process and our ability to analyze the cytotoxic or
neuroprotective effects of chemicals, drugs, and so forth
(Figure 1).
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Figure 1: Possible cellular sources for modeling Parkinson’s disease in vitro. Somatic cells from patient with PD can be reprogrammed into
iPSC and differentiated into mesencephalic dopaminergic neurons (1a)–(5). ESC and NPC can be genetically modified by inserting specific
mutations related with PD and be differentiated. Alternatively, somatic cells can be directly converted into dopaminergic neurons (1b).
4. Stem Cell Types and Properties
Stem cells are characterized by the ability to renew themselves
through mitotic cell division and differentiate into a diverse
range of specialized cell types. They can be classified
according to their potential to differentiate into specialized
cells. The first type is totipotent stem cells that can give
rise to an entire viable organism, including placental cells.
The zygote and the cells at the very early stages following
fertilization (i.e., the 2-cell stage) are considered totipotent.
The second type is pluripotent stem cells, which have
the capacity to develop into specialized cells of the three
germ layers (ectoderm, mesoderm, and endoderm) except
extraembryonic tissues, such as placenta. The first and best
described are Embryonic Stem Cells (ESCs), derived from the
inner cell mass of the blastocyst [17]. Theoretically, because
of their properties, these cells may constitute an optimal
source of DA neurons for cell-replacement therapies and
drug screening experiments; however, to achieve this aim, it
is essential to have an efficient protocol for differentiation
into functional midbrain DA neurons. In fact, cultures
enriched in human DA neurons have been generated from
ESC using a variety of methods, such as the use of the
coculture with stromal cells, growth factors, secreted factors,
transcription factors, and morphogens, with some beneficial
effects having been demonstrated after transplantation of
these cells in animal models of PD [18–21].
Recent advances in stem cell biology have led to
technologies to reprogram somatic cells from the adult
human to a state of pluripotency [22–24]. The first reported
lines of reprogrammed cells, termed induced pluripotent
stem cells (iPSCs), were originally generated by introducing
four transcription factors: Oct3/4, Sox2, Klf4, and c-myc
(or Nanog, Lin28) into adult fibroblasts. These cells are
similar to hESC in morphology, gene expression profile,
and differentiation potential. The induced iPSC technology
offers new possibilities for biomedical research and clinical
applications, as these cells could be used as an in vitro
cellular model of PD, and for autologous transplantation
(theoretically, no immunosuppressive therapy would be
necessary). For this reason, it is essential to obtain an efficient
and strict differentiation protocol of hiPSC into midbrain
DA-like neurons. In addition, hiPSC do not raise ethical
concerns since they are derived from somatic cells, following
routine tissue donation procedures.
The third type of stem cells is multipotent stem cells
that only generate specific lineages of cells, like Neural Stem
Cells (NSCs) that are derived from neural tissues. These
cells are self-renewing and differentiate into lineage-specific
neural precursor or progenitor cells (NPCs) that can give rise
to all cell types (neurons, astrocytes, and oligodendrocytes)
of the nervous system [25]. However, although sometimes
not evident from the literature, hNSCs—particularly those
derived from the ventral mesencephalon (vm)—grow poorly
in culture, their properties change over time (passages), and
they lose their ability to generate neurons, particularly DA
neurons, thus making them difficult to use on a large-scale
approach [25, 26].
5. Directed Differentiation of Pluripotent Stem
Cells into DA Neurons
The necessary first step towards PD modeling is the pro-
duction, in enough number, of disease neuronal phenotypes,
that is, DA neurons, from differentiated human pluripotent
stem cells in vitro. Current in vitro differentiation from either
ESC or iPSC includes protocols based on embryoid body
formation or the use of stromal feeder coculture [18–20, 27–
34]. Efficient generation of DA neurons needs the combined
actions of factors such as Noggin, FGF8, Sonic Hedgehog,
Retinoic Acid, Wnt1, BNDF, GNDF, Ascorbic Acid, cyclic-
AMP, and Wnt5 [18, 20, 27, 29], similar to those secreted
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factors present during development [35]. In vitro, early expo-
sure to Noggin [20, 27], antagonist of the BMP signaling, or
to inhibitors of Lefty/Activin/TGFβ pathways allows a highly
efficient feeder-free neural induction in adherent cultures
and permits a dopaminergic and motoneuronal potential
[18, 20]. In contrast, neural induction can be obtained in
the absence of factors and coculturing ES with stromal feeder
cell lines [28]. Subsequently, dopaminergic patterning is
established by the combined action of FGF8, FGF2, SHH
[18, 20], GNDF [28], BDNF, and ascorbic acid. Finally,
terminal differentiation is accomplished after withdrawal of
SHH and FGF8 and promoted by the presence of ascorbic
acid, GDNF, TGFb-1, cyclic-AMP, and Wnt5 [29].
Alternatively, DA neurons can be obtained by the
forced expression of transcription factors crucial for ventral
midbrain identity [36–40]. Thus overexpression of Lmx1a
induces DA neurons from murine ESC [36, 37], hESC, and
hiPSC [41]; moreover, neuron precursors derived from hESC
overexpressing Lmx1a are able to survive and differentiate
when grafted into the brain of adult mice [41].
Although iPSC and ESC differ in their origin, differ-
entiation of both cell types into DA neurons seems to
use similar cues and signals. The analysis by transcriptome
revealed no differences in the level of expression of genes
involved in dopaminergic differentiation such as EN1, Nurr1,
TH, AADC, and Girk2; moreover analysis of genes involved
in imprinting, cell cycle regulation, and reprogramming
revealed no significant differences [34].
6. Induced Pluripotent Stem Cells as In Vitro
Model of PD
Derivation of pluripotent stem cells from somatic tissues has
provided researchers with a source of patient-specific stem
cells. In addition, iPSC technology renders a good model in
vitro for diseases and drug treatment essays [42].
So far, some groups have developed protocols to increase
the yield of DA neurons generation from iPSC from either
human or mice [22, 30–32, 42, 43]. In murine models,
following protocols developed for ES cells, neural precursor
cells and DA neurons were obtained from healthy iPSC
[33]. Moreover, derived cells transplanted into the develop-
ing brain are able to integrate, migrate, differentiate, and
display electrophysiological functions showing spontaneous
action potential currents in the host brain. Cells deriva-
tives included glutamatergic, GABAergic, and DA neurons.
Importantly, grafts derived from iPSC are capable to restore
motor function in animal models for PD [33] suggesting that
dopaminergic neurons derived from iPSC are functional in
vivo.
In humans, DA neurons derived from iPSC can be
obtained from healthy donors [34] or patients with PD
caused by idiopathic conditions [32, 42] or by mutation
[30, 31]. For instance, DA neurons can be generated from
iPSCs that carry a mutation in LRRK2 gene (p.G2019S),
the most common PD-related mutation [8, 10]. After
reprogramming, culture differentiation protocol using feed-
ers, iPSC-p.G2019S generated a significant number of DA
neurons up to 55 days of differentiation; furthermore,
these neurons show properties of mature neurons, including
the expression of synaptotagmin-1, a protein localized to
synaptic vesicles, and the ability of fire action potentials
in response to depolarizing current injections and produce
spontaneous synaptic activities. Moreover these DA neurons
are able to synthesize and release dopamine in response to
stimulation with high potassium [30]. A detailed phenotypic
characterization related with the PD at day 35 reveals that
iPSC-p.G2019S expressed higher levels of genes involved in
oxidative stress pathways than controls; indeed trials testing
the peroxide-induced cell death show that G2019S-iPSC-
derived DA neurons may be more susceptible to oxidative
stress and show significantly more cell death than controls.
Due to the phenotypes in iPSC-p.G2019S resemblance to
the PD phenotype that provides a good model for the in
vitro disease, this system has been used to test some potential
drugs for the treatment of PD [30].
In contrast, other models of PD based on triplica-
tion of α-synuclein locus had been generated [31]. This
mutation causes a fully penetrant and aggressive form of
PD with dementia [8–10] compared with the homozygous
G2019S mutation of LRRK2 that has incomplete penetrance,
even with homozygous conditions [44]. Using a feeder-
free monolayer differentiation method, iPSC differentiated
efficiently into midbrain DA neurons after 20 to 31 days when
α-synuclein protein could be detected and secreted to media
[31]. In addition to this model, fibroblasts obtained from
a patient carrying the A53T (G209A) α-synuclein mutation
have been reprogrammed into iPSC and successfully dif-
ferentiated into DA neurons [43], which could serve as a
good model for the in vitro analysis; nevertheless, further
phenotypic characterization of cells related with PD remains
to be studied.
Other models include those DA neurons derived from
iPSC and obtained from patient with idiopathic conditions
[32, 42]. After reprogramming patient iPSC, cells were
differentiated into DA neurons using the stromal feeder
cell-based differentiation protocol. At 42 days, these cells,
including DA and non-DA neurons, were transplanted into
the striatum of healthy animals. 8 weeks after implantation
DA neurons marked with the nigral marker Girk-2 were
found into the viable grafts. Moreover, transplantation
experiments by engrafting DA neurons derived from iPSC
on animal models of PD showed functional effects, although
only a few of them sent their axons toward the DA-depleted
host striatum. Analysis of behavior in animal models of PD
exhibited a significant improvement of motor dysfunction
[32, 34]. In summary, several evidences suggest that DA
neurons from pluripotent stem cells are functional in both in
vitro and in vivo conditions. Hence, some of the DA neurons
derived from PD patients that exhibit some characteristic
phenotypes of the disease could provide a valuable cellular
source to study in vitro the PD. For instance, iPSCs derived
from PD patients carrying a nonsense (c.1366C>T; p.Q456X)
or missense (c.509T>G; p.V170G) mutations in the PINK1
gene have been used to examine the role of endogenous
PINK1 in dopaminergic neurons [45]. PINK1 encodes a
kinase localized on the outer mitochondrial membrane and
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Table 1: Examples of in vitro models to study Parkinson’s disease derived from patient iPSC.
Gene Genetic disease Genetic alteration References
SNCA Autosomal dominant Triplication of α-synuclein locus [31]
G209A mutation [43]
LRRK2 Autosomal dominant p.G2019S mutation [30]
PINK1 Autosomal recessive p.Q456X and p.V170G mutation [45]
Idiopathic condition Idiopathic [32, 42]
is implicated in the regulation of mitochondrial degradation
[11]; mutations in PINK1 have been associated with PD [8,
11]. In contrast, Parkin proteins function as an E3 ubiquitin
ligase and are localized in the cytosol [11]. In addition,
Parkin can be translocated to damaged mitochondria in
a PINK1-dependent manner [44]. Thus, experiments on
DA neurons from PD patients exhibit impairment in the
translocation of Parkin of mutant PINK1 iPSC cell-derived
DA neurons compared to controls. Moreover, rescue experi-
ments by overexpressing wild type PINK1 in PINK1 mutant
neurons restore the translocation of Parkin to mitochondria
[45]. In conclusion, DA neurons obtained in vitro from PD
patients are a suitable model to study the pathogenesis of PD
at cellular level (Figure 1; Table 1).
However, several challenges must be overcome before
successful implementation of iPSC-based drug screening and
pathway discovery can be achieved (Figure 1). The most
critical issue is whether the PD phenotype can be reproduced
in vitro, and if so, whether it can accurately predict disease
behavior in vivo. PD can be difficult to model, since it
occurs late in life and is caused by complex environmental
and genetic factors. In fact, in one study that generated DA
neurons from iPSC derived from patients with sporadic PD,
no obvious abnormalities could be detected [42], indicating
that additional stressors may be required to reveal the disease
phenotype. Nevertheless, the study of rare family forms of
the disease that are associated with specific gene mutations
can provide valuable information on the general disease
mechanisms. It would be interesting to study whether the
iPSC generated from familial PD patients could exhibit
disease genotypes and phenotypes in vitro.
Other additional limitations are related to the low
efficiency and high variability of the reprogramming process
and the heterogeneity of the maturation stage and cellular
phenotypes obtained after differentiation of iPSC into DA
neurons. Even though great progress has been made, our
understanding of the factors controlling the induction and
specification of DA neuronal fate is far for complete. Further
advances in the field will facilitate the generation of clinically
relevant DA neurons at least in vitro.
7. Direct Conversion of Somatic Cells
to DA Neurons
Recent reports have demonstrated that human somatic cells
can be directly converted to functional neurons, named
induced neurons (iNs) by using combined expression of
defined factors (Ascl1, Brn2, and Myt1l) [39]; the same
authors showed that these neurons can be directed toward
dopaminergic phenotype by overexpression of Lmx1a and
FoxaA2 (two genes involved in DA neuron generation during
development). A different cocktail of factors, with only
three transcription factors (Mash1, Nurr1, and Lmx1a), were
used by other group for direct generation of functional
DA neurons (iDA, induced dopamine neurons) from adult
fibroblasts from healthy donors and PD patients [38].
Reprogrammed cells were similar to brain DA neurons in
gene expression and dopamine release. However the possible
PD phenotype of the generated iDA from PD patients
remains to be demonstrated.
This strategy opens new possibilities for regenerative
therapies and diseases modelling of PD. Cells generated
via direct conversion do not pass through a pluripotent or
progenitor state, are probably not tumorigenic, and may
serve as an interesting alternative to iPSCs for generating
patient and/or disease-specific neurons. However, to be
clinically relevant, the overall cell conversion process needs
to be highly efficient in order to obtain enough amounts of
cells available to study the disease or grafting studies. Both
iPSC and iDA cells circumvent the ethical concerns related
to embryonic stem cell derivation and potential issues of
allogenic rejection in cell-replacement therapy studies.
8. Future Prospects
Many questions that define the underlying genesis of the
neuronal death in disorders like PD remain unanswered,
with evidence suggesting a key role for mitochondrial
dysfunction. In this sense, stem cells, in general, and mainly
pluripotent stem cells can provide an unlimited source of
human DA neurons for in vitro studies of neurotoxic and
neuroprotective processes that might be related to PD.
iPSC technology has been shown to be of specific
interest in monogenic diseases, providing innovative models
to understand disease pathology. Modelling late-onset and
multifactorial diseases, such as PD, may be more difficult
and probably will require additional advances. However, the
study or rare forms of PD, associated with specific gene
mutations, can provide valuable information on the general
disease mechanism. Importantly, patient cell donors can be
genetically modified in order to correct mutations. This
modification permits the generation of healthy and mutated
DA neurons from the same donor, improving the compar-
ative analysis between both cell types in isogenic conditions.
Indeed, genetic repairment in iPSC could provide also a good
tool in the advances toward iPSC-based cell-replacement
therapies.
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Even though the large body of current research iPSC
technology is still in its infancy, several limitations need to
be solved in the near future, for example, standardization
in order to obtain medically relevant cells, avoiding contact
with animal products, and improvement of reprogramming
methods in order to increase efficiency and homogeneity and
to avoid tumorigenic properties of iPSC.
Some of these limitations could be circumvent with
another innovative approach, “direct reprogramming” of
somatic cells from patients to specific neurons (iN). Rapid
and efficient generation of patient-specific DA neurons
through direct reprogramming may yield many advantages
in the screening of pharmaceutical compounds as well as
cellular material for analysis of molecular pathways of the
disease and for transplantation studies.
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